SCHEMBL19670102

SCHEMBL19670102

COc1ccc(SCCCC/N=N/c2c(-c3ccc(OC)cc3)[nH]c3ccccc23)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.51
▸ KDM4E B2RXH2 3/20 0.51
▸ KMT2A Q03164 2/20 0.51
▸ ALDH1A1 P00352 3/20 0.45
▸ SMN1; SMN2 Q16637 3/20 0.45
▸ HPGD P15428 2/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ PPARG P37231 1/20 0.45
▸ NCOA2 Q15596 1/20 0.45
▸ NCOA1 Q15788 1/20 0.45
▸ TUBB4A P04350 1/20 0.43
▸ TUBB P07437 1/20 0.43
▸ TUBA3C P0DPH7 1/20 0.43
▸ TUBA1B P68363 1/20 0.43
▸ TUBA4A P68366 1/20 0.43
▸ TUBB4B P68371 1/20 0.43
▸ TUBB3 Q13509 1/20 0.43
▸ TUBB2A Q13885 1/20 0.43
▸ TUBB8 Q3ZCM7 1/20 0.43
▸ TUBA3E Q6PEY2 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19670109 0.76 KMT2A (0.47) MAPTKDM4EKMT2AALDH1A1SMN1; SMN2
SCHEMBL18160148 0.75 GSK3B (0.55) MAPTKDM4EKMT2AALDH1A1SMN1; SMN2
SCHEMBL18180611 0.75 GSK3B (0.55) MAPTKDM4EKMT2AALDH1A1SMN1; SMN2
SCHEMBL18180508 0.74 KMT2A (0.54) MAPTKDM4EKMT2AALDH1A1SMN1; SMN2
SCHEMBL5170737 0.69 ALDH1A1 (0.61) MAPTKDM4EKMT2AALDH1A1SMN1; SMN2
SCHEMBL5167250 0.69 ALDH1A1 (0.56) MAPTKDM4EKMT2AALDH1A1SMN1; SMN2
SCHEMBL5172139 0.68 ALDH1A1 (0.54) MAPTKDM4EALDH1A1SMN1; SMN2LMNA
SCHEMBL28906514 0.66 KDM4E (0.58) MAPTKDM4EKMT2AALDH1A1SMN1; SMN2
SCHEMBL9808184 0.66 ALDH1A1 (0.56) MAPTKDM4EKMT2AALDH1A1SMN1; SMN2
SCHEMBL31397686 0.66 TUBB4A (0.68) MAPTKDM4EKMT2AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10239834-B2 Antibiotic sensitivity-restoring and photosensitive agents NEW MEXICO TECH UNIVERSITY RESEARCH PARK CORPORATION (US) 2019-03-26 — — US disclosed
US-20180155286-A1 ANTIBIOTIC SENSITIVITY-RESTORING AND PHOTOSENSITIVE AGENTS NEW MEXICO TECH UNIVERSITY RESEARCH PARK CORPORATION 2018-06-07 — — US disclosed
US-9834514-B2 Antibiotic sensitivity-restoring and photosensitive agents NEW MEXICO TECH RESEARCH FOUNDATION (US) 2017-12-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10239834-B2 Antibiotic sensitivity-restoring and photosensitive agents XPA, PPOX, ALAD MAPT 2538/4885KDM4E 1516/4885KMT2A 2258/4885
US-20180155286-A1 ANTIBIOTIC SENSITIVITY-RESTORING AND PHOTOSENSITIVE AGENTS XPA, PPOX, ALAD MAPT 2538/4885KDM4E 1516/4885KMT2A 2258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback